keyword
MENU ▼
Read by QxMD icon Read
search

non-small cell lung cancer

keyword
https://www.readbyqxmd.com/read/29031195/ginsenoside-rg3-attenuates-cisplatin-resistance-in-lung-cancer-by-downregulating-pd-l1-and-resuming-immune
#1
Zhansheng Jiang, Yanfang Yang, Yinli Yang, Yu Zhang, Zhensong Yue, Zhanyu Pan, Xiubao Ren
Programmed death ligand 1 (PD-L1) as one the most important immune checkpoint was verified to involve in chemotherapy resistance in non-small cell lung cancer (NSCLC). Ginsenoside Rg3 is isolated from Chinese herb-Panax ginseng which is recognized to boost immune and has anti-cancer activity against a majority of carcinomas including NSCLC. In this study, we aim to identify whether Rg3 could attenuate the PD-L1 expression induced by resistance to cisplatin and draw out the underlying mechanisms of PD-L1 in this process...
October 11, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29029062/multicentric-evaluation-of-the-impact-of-central-tumour-location-when-comparing-rates-of-n1-upstaging-in-patients-undergoing-video-assisted-and-open-surgery-for-clinical-stage-i-non-small-cell-lung-cancer
#2
Herbert Decaluwé, René Horsleben Petersen, Alex Brunelli, Cecilia Pompili, Agathe Seguin-Givelet, Lucile Gust, Clemens Aigner, Pierre-Emmanuel Falcoz, Philippe Rinieri, Florian Augustin, Youri Sokolow, Ad Verhagen, Lieven Depypere, Kostas Papagiannopoulos, Dominique Gossot, Xavier Benoit D'Journo, Francesco Guerrera, Jean-Marc Baste, Thomas Schmid, Alessia Stanzi, Dirk Van Raemdonck, Jeremy Bardet, Pascal-Alexandre Thomas, Gilbert Massard, Steffen Fieuws, Johnny Moons, Christophe Dooms, Paul De Leyn, Henrik Jessen Hansen
OBJECTIVES: Large retrospective series have indicated lower rates of cN0 to pN1 nodal upstaging after video-assisted thoracic surgery (VATS) compared with open resections for Stage I non-small-cell lung cancer (NSCLC). The objective of our multicentre study was to investigate whether the presumed lower rate of N1 upstaging after VATS disappears after correction for central tumour location in a multivariable analysis. METHODS: Consecutive patients operated for PET-CT based clinical Stage I NSCLC were selected from prospectively managed surgical databases in 11 European centres...
September 27, 2017: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/29028092/long-non-coding-rna-ror-is-a-novel-prognosis-factor-associated-with-non-small-cell-lung-cancer-progression
#3
C-H Qu, Q-Y Sun, F-M Zhang, Y-M Jia
OBJECTIVE: The aim of the present study was to determine the expression levels of long intergenic non-protein coding RNA, regulator of reprogramming (linc-ROR) in non-small-cell lung cancer (NSCLC) patients and to further explore the prognostic value of this lncRNA. PATIENTS AND METHODS: In our investigation, we determined the expression of linc-ROR in human NSCLC tissues and matched normal lung tissues by quantitative Real-time-PCR analysis. Also, correlations between linc-ROR expression and the clinicopathological features were evaluated...
September 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29028091/investigation-of-serum-mir-411-as-a-diagnosis-and-prognosis-biomarker-for-non-small-cell-lung-cancer
#4
S-Y Wang, Y Li, Y-S Jiang, R-Z Li
OBJECTIVE: Biomarkers in blood have become increasingly appreciated in the diagnosis and prognosis of non-small cell lung cancer (NSCLC). The purpose of the current study was to explore potential diagnostic and prognostic value of serum miR-411 in NSCLC patients. PATIENTS AND METHODS: 153 patients with NSCLC and 75 healthy controls were enrolled in the study. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed to determine the expression level of serum miR-411 in NSCLC patients and healthy controls...
September 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29027005/utility-of-the-revised-edmonton-symptom-assessment-system-esas-r-and-the-patient-reported-functional-status-prfs-in-lung-cancer-patients
#5
M N Yogananda, Valliappan Muthu, Kuruswamy Thurai Prasad, Adarsh Kohli, Digambar Behera, Navneet Singh
BACKGROUND: Symptom palliation is an important objective of treatment in advanced/metastatic lung cancer (LC). Significant psychological, minor physical symptoms and several social/emotional issues often go unnoticed. This prospective study aimed to evaluate utility of patients' perspectives [self-reported symptom assessment by revised Edmonton Symptom Assessment System (ESAS-r) and self-reported functional status by Patient-Reported Functional Status (PRFS)] amongst LC patients undergoing chemotherapy...
October 12, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29026205/non-small-cell-lung-cancer-where-there-s-smoke
#6
Ulrike Harjes
No abstract text is available yet for this article.
October 13, 2017: Nature Reviews. Cancer
https://www.readbyqxmd.com/read/29026165/appropriate-surgical-modalities-for-stages-t2a-and-t2b-in-the-eighth-tnm-classification-of-lung-cancer
#7
Fenglong Bie, Xiao Qu, Xudong Yang, Zhaofei Pang, Yufan Yang, Shaorui Liu, Wei Dong, Jiajun Du
Patients with tumors of 3 to 5 cm were divided into stages T2a (3 to 4 cm) and T2b (4 to 5 cm) based on the 8(th) tumor-node-metastasis staging system for lung cancer. The objective of our study was to explore appropriate surgical modalities for the new stages, T2a and T2b. We selected 6,996 node-negative non-small-cell lung cancer patients with tumor sizes of 3 to 5 cm, diagnosed between 2009 and 2013, from the Surveillance, Epidemiology, and End Results (SEER) program. The Pearson [Formula: see text]...
October 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29025989/low-level-endogenous-prostate-specific-membrane-antigen-psma-expression-in-non-prostatic-tumor-xenografts-is-sufficient-for-in-vivo-tumor-targeting-and-imaging
#8
Sridhar Nimmagadda, Mrudula Pullambhatla, Ying Chen, Princy Parsana, Ala Lisok, Samit Chatterjee, Ronnie Mease, Steven P Rowe, Shawn E Lupold, Kenneth J Pienta, Martin G Pomper
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and within the neovasculature of other solid tumors. The non-prostatic expression of PSMA has been reported exclusively within the neovasculature endothelial cells of non-prostate cancers, however, there are few reports on PSMA expression on epithelial cells. Herein we describe PSMA expression in non-prostatic epithelial cells and characterize the potential of PSMA-binding agents to non-invasively detect that expression. METHODS: PSMA expression data was extracted from publicly available genomic databases...
October 12, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29025589/potential-circulating-mirna-signature-for-early-detection-of-nsclc
#9
Ayda Arab, Morteza Karimipoor, Shiva Irani, Arda Kiani, Sirous Zeinali, Elham Tafsiri, Kambiz Sheikhy
Circulating microRNAs (c-miRNAs) are promising biomarkers for screening, early detection and prognosis of cancer. The purpose of this investigation was to identify a panel of c-miRNAs in plasma that could contribute to early detection of non-small cell lung cancer (NSCLC). We profiled the expression of 44 unique plasma miRNAs in training set of 34 NSCLC patients and 20 matched healthy individuals by miRCURY LNA™ Universal RT microRNA PCR Panel and calculated dysregulation fold changes using the 2-ΔΔCt equation...
October 2017: Cancer Genetics
https://www.readbyqxmd.com/read/29025258/microrna-373-inhibits-cell-proliferation-and-invasion-via-targeting-brf2-in-human-non-small-cell-lung-cancer-a549-cell-line
#10
Lei Wang, Junfeng Qu, Li Zhou, Fei Liao, Ju Wang
Purpose: The purpose of this study was to investigate the biological role and mechanism of miR-373 targeting of TFIIB-related factor 2 (BRF2) in the regulation of non-small cell lung cancer (NSCLC) cells. Methods: miRNA microarray chip analysis of four paired NSCLC and adjacent non-tumor tissues was performed. Quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting were used to detect the expression levels of miR-373 and BRF2 in NSCLC tissues and cell lines...
October 12, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/29025156/risk-factors-associated-with-mortality-from-vascular-thromboembolic-events-in-patients-diagnosed-with-non-small-cell-lung-cancer-a-population-based-analysis
#11
Xian-Jun He, Ying-Ying Wu, Ming-Rong Xia, Zhi-Qiang Li, Ming Zhao, Quan-De Dai, Jian-Ping Zhang, Jian-Hua Xia, Jie-Wen Zhang
Background: Lung cancer patients are at increased risk for vascular events possibly due to cancer induced hypercoagulation. Aim: The purpose of this study was to evaluate risk factors associated with the mortality from vascular thromboembolic events in patients diagnosed with non-small cell lung cancer (NSCLC). Design: Retrospective population-based analysis. Methods: We used Surveillance, Epidemiology, and End Results Program for 2004 - 2013 and evaluated 199,337 patients with NSCLC...
August 24, 2017: QJM: Monthly Journal of the Association of Physicians
https://www.readbyqxmd.com/read/29024939/ailanthone-inhibits-non-small-cell-lung-cancer-cell-growth-through-repressing-dna-replication-via-downregulating-rpa1
#12
Zhongya Ni, Chao Yao, Xiaowen Zhu, Chenyuan Gong, Zihang Xu, Lixin Wang, Suyun Li, Chunpu Zou, Shiguo Zhu
BACKGROUND: The identification of bioactive compounds from Chinese medicine plays a crucial role in the development of novel reagents against non-small lung cancer (NSCLC). METHODS: High throughput screening assay and analyses of cell growth, cell cycle, apoptosis, cDNA microarray, BrdU incorporation and gene expression were performed. RESULTS: Ailanthone (Aila) suppressed NSCLC cell growth and colony formation in vitro and inhibited NSCLC tumour growth in subcutaneously xenografted and orthotopic lung tumour models, leading to prolonged survival of tumour-bearing mice...
October 12, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/29024929/inhibition-of-microrna-21-5p-promotes-the-radiation-sensitivity-of-non-small-cell-lung-cancer-through-hmsh2
#13
Yu Song, Yun Zuo, Xiao-Lan Qian, Zhi-Peng Chen, Shao-Kai Wang, Lei Song, Li-Ping Peng
BACKGROUND: This study aimed to explore the effects of microRNA-21-5p (miR-21-5p) on the radiation sensitivity of non-small cell lung cancer (NSCLC) and the involvement of human MutS homolog 2 (hMSH2) One hundred fourteen NSCLC patients at stage II or III who received surgery and postoperative radiotherapy were enrolled in this study. METHODS: The patients were assigned into radiation-sensitive and -insensitive groups. NSCLC A549 cells were transfected to generate control, Negative control (NC), miR-21-5p inhibitor, miR-21-5p mimic, small interfering hMSH2 (sihMSH2), miR-21-5p inhibitor + sihMSH2 and hMSH2 overexpression groups...
October 9, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/29024815/identification-of-a-novel-autophagic-inhibitor-cepharanthine-to-enhance-the-anti-cancer-property-of-dacomitinib-in-non-small-cell-lung-cancer
#14
Zheng-Hai Tang, Wen-Xiang Cao, Xia Guo, Xiao-Yang Dai, Jia-Hong Lu, Xiuping Chen, Hong Zhu, Jin-Jian Lu
Inhibition of autophagy is a promising strategy for non-small cell lung cancer (NSCLC) treatment, which is in the clinical trials. However, only chloroquine is used in clinic as an autophagic inhibitor and the inhibitory effect of chloroquine on autophagy is finite. Therefore, the development of an alternative autophagic inhibitor for NSCLC therapy becomes necessary. In the present study, cepharanthine (CEP), an alkaloid extracted from Stephania cepharantha Hayata, was identified as a novel autophagic inhibitor in NSCLC cells...
October 9, 2017: Cancer Letters
https://www.readbyqxmd.com/read/29024631/luteoloside-induces-g0-g1-arrest-and-pro-death-autophagy-through-the-ros-mediated-akt-mtor-p70s6k-signalling-pathway-in-human-non-small-cell-lung-cancer-cell-lines
#15
Menglu Zhou, Shuying Shen, Xin Zhao, Xingguo Gong
Autophagy has attracted a great deal of interest in tumour therapy research in recent years. However, the anticancer effect of luteoloside, a naturally occurring flavonoid isolated from the medicinal plant Gentiana macrophylla, on autophagy remains poorly understood in human lung cells. In the present study, we have investigated the anticancer effects of luteoloside on non-small cell lung cancer (NSCLC) cells and demonstrated that luteoloside effectively inhibited cancer cell proliferation, inducing G0/G1phase arrest associated with reduced expression of CyclinE, CyclinD1 and CDK4; we further found that treatment with luteoloside did not strongly result in apoptotic cell death in NSCLC (A549 and H292) cells...
October 9, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29024572/radiological-manifestations-of-immune-related-adverse-effects-observed-in-patients-with-melanoma-undergoing-immunotherapy
#16
Parveen Sidhu, Alexander M Menzies, Georgina Long, Matteo Carlino, Shirleen Lorens, Rony Kapoor
Immunotherapy drugs work by stimulating the patient's own immune system to recognize and destroy cancer cells. This subclass of drugs is increasingly administered to patients with advanced melanoma. They are also commonly incorporated into other cancer therapies such as non-small cell lung cancer, renal cancer, head and neck cancers and Hodgkin lymphoma. The most commonly administered immunotherapeutic agents in the treatment of melanoma include programmed cell death protein 1 (PD-1) inhibitors, cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitors and a subclass of cytokines...
October 11, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/29024471/programmed-death-ligand-1-expression-in-non-small-cell-lung-carcinoma-comparison-among-cytology-small-biopsy-and-surgical-resection-specimens
#17
Jonas J Heymann, William A Bulman, David Swinarski, Carlos A Pagan, John P Crapanzano, Mehrvash Haghighi, Ladan Fazlollahi, Mark B Stoopler, Joshua R Sonett, Adrian G Sacher, Catherine A Shu, Naiyer A Rizvi, Anjali Saqi
BACKGROUND: One immunotherapeutic agent for patients with advanced non-small cell lung carcinoma, pembrolizumab, has a companion immunohistochemistry (IHC)-based assay that predicts response by quantifying programmed death-ligand 1 (PD-L1) expression. The current study assessed the feasibility of quantifying PD-L1 expression using cytologic non-small cell lung carcinoma specimens and compared the results with those from small biopsy and surgical resection specimens. METHODS: PD-L1 expression was quantified using the IHC-based 22C3 pharmDx assay, with "positivity" defined as staining in ≥50% viable tumor cells; ≥ 100 tumor cells were required for test adequacy...
October 12, 2017: Cancer
https://www.readbyqxmd.com/read/29024297/reducing-dose-to-the-lungs-through-loosing-target-dose-homogeneity-requirement-for-radiotherapy-of-non-small-cell-lung-cancer
#18
Junjie Miao, Hui Yan, Yuan Tian, Pan Ma, Zhiqiang Liu, Minghui Li, Wenting Ren, Jiayun Chen, Ye Zhang, Jianrong Dai
It is important to minimize lung dose during intensity-modulated radiation therapy (IMRT) of nonsmall cell lung cancer (NSCLC). In this study, an approach was proposed to reduce lung dose by relaxing the constraint of target dose homogeneity during treatment planning of IMRT. Ten NSCLC patients with lung tumor on the right side were selected. The total dose for planning target volume (PTV) was 60 Gy (2 Gy/fraction). For each patient, two IMRT plans with six beams were created in Pinnacle treatment planning system...
October 11, 2017: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/29023696/tumor-infiltrating-tryptase-mast-cells-predict-unfavorable-clinical-outcome-in-solid-tumors
#19
Guoming Hu, Shimin Wang, Pu Cheng
The prognostic role of tumor-infiltrating tryptase(+) mast cells in human solid tumors remains controversial. Herein, we conducted a meta-analysis including 28 published studies with 4224 patients identified from PubMed and EBSCO to assess the prognostic impact of tumor-infiltrating tryptase(+) mast cells in human solid tumors. We found that tryptase(+) mast cell infiltration significantly decreased overall survival (OS) and disease-free survival (DFS) in all types of solid tumors. In stratified analyses, tryptase(+) mast cell infiltration was significantly associated with worse OS in non-small cell lung cancer, hepatocellular carcinoma and 5-year survival in colorectal cancer...
October 12, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29023213/nivolumab-versus-docetaxel-in-previously-treated-patients-with-advanced-non-small-cell-lung-cancer-two-year-outcomes-from-two-randomized-open-label-phase-iii-trials-checkmate-017-and-checkmate-057
#20
Leora Horn, David R Spigel, Everett E Vokes, Esther Holgado, Neal Ready, Martin Steins, Elena Poddubskaya, Hossein Borghaei, Enriqueta Felip, Luis Paz-Ares, Adam Pluzanski, Karen L Reckamp, Marco A Burgio, Martin Kohlhäeufl, David Waterhouse, Fabrice Barlesi, Scott Antonia, Oscar Arrieta, Jérôme Fayette, Lucio Crinò, Naiyer Rizvi, Martin Reck, Matthew D Hellmann, William J Geese, Ang Li, Anne Blackwood-Chirchir, Diane Healey, Julie Brahmer, Wilfried E E Eberhardt
Purpose Nivolumab, a programmed death-1 inhibitor, prolonged overall survival compared with docetaxel in two independent phase III studies in previously treated patients with advanced squamous (CheckMate 017; ClinicalTrials.gov identifier: NCT01642004) or nonsquamous (CheckMate 057; ClinicalTrials.gov identifier: NCT01673867) non-small-cell lung cancer (NSCLC). We report updated results, including a pooled analysis of the two studies. Methods Patients with stage IIIB/IV squamous (N = 272) or nonsquamous (N = 582) NSCLC and disease progression during or after prior platinum-based chemotherapy were randomly assigned 1:1 to nivolumab (3 mg/kg every 2 weeks) or docetaxel (75 mg/m(2) every 3 weeks)...
October 12, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
15685
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"